1887
Volume 2010, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

A middle-aged lady admitted with metastatic breast cancer developed acute respiratory problems with bilateral pulmonary infiltrates after five days of cytotoxic administration, as an acute adverse drug reaction to the docetaxel that resolved completely after high dosage of dexamethasone.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2010.1.21
2010-06-01
2019-11-19
Loading full text...

Full text loading...

References

  1. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005; 65:17, : 25, 13–31.
    [Google Scholar]
  2. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999; 36:2:99114.
    [Google Scholar]
  3. Taxotere.com for Healthcare Professionals: Efficacy and Safety. Sanofi-aventis U.S. LLC. http://www.taxotere.com/professional/about/efficacy_safety.do (6 Nov 2008).
  4. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. London: Churchill Livingstone 2003;:694698.
    [Google Scholar]
  5. Kunitah H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non smallcell lung cancer: A Japanese cooperative study. J Clin Oncol. 1996; 14::16491665.
    [Google Scholar]
  6. Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001; 85::12471250.
    [Google Scholar]
  7. Rowinsky EK, Donehower RC. The clinical pharmacology ofpaclitaxel (TAXOL(r)). Semin Oncol. 1993; 20:Suppl 3:16.
    [Google Scholar]
  8. Horwitz SB. Mechanism of action oftaxol. Trends Pharmacol Sci. 1992; 13::134.
    [Google Scholar]
  9. Thomas AL, Cox G, Sharma RA. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: Report of a phase l/lI dose-escalating study. Eur J Cancer. 2000; 36::2329.
    [Google Scholar]
  10. Dunsford ML, Mead GM, Bateman AC. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999; 10::943.
    [Google Scholar]
  11. Yu TK, Whitman GJ, Thames HD. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004; 96::1676.
    [Google Scholar]
  12. Taghian AG, Assaad SI, Niemierko A. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001; 93::1806.
    [Google Scholar]
  13. Beal K, Hudis C, Norton L. Radiation pneumonitis in breast cancer patients treated with taxanes: Does sequential radiation therapy lower the risk? Breast J. 2005; 11::317.
    [Google Scholar]
  14. Hamourl M, Mittal TK, Bell AD. Banner NR of Heart Lung Transplant. 2006 Feb; 25:2:241244, . Epub 2995 Dec 20.
    [Google Scholar]
  15. Holy PY, Luna MA, Mackay B, Bedrossian CWM. Bleomycin induced hypersensitivity pneumonitis (1978). AM Int Med. 1978; 88::4749.
    [Google Scholar]
  16. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Parti: Cytotoxic drugs. Am Rev Respir Dis. 1986; 133::321321.
    [Google Scholar]
  17. Guillon JM, Joly P, Austrian B, Denis MA. Minocycline-induced cellmediated hypersensitivity pneumonitis. Am Int Med. 1992; 117::467481.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2010.1.21
Loading
  • Article Type: Case Report
Keyword(s): Breast Cancer , Docetaxel , Drug Induced Interstitial and pneumonitis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error